Pages that link to "Q44700335"

The following pages link to Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission (Q44700335):

Displaying 20 items.

• Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report (Q35735986) (← links)
• Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy (Q36419964) (← links)
• Relapsed Hodgkin lymphoma: management strategies (Q37008427) (← links)
• Current approaches to the management of pediatric Hodgkin lymphoma (Q37706528) (← links)
• Comparison of the long-term mortality in Hodgkin's disease patients with that of the general population. (Q38498553) (← links)
• Update of results of autologous bone marrow transplantation in lymphoma (Q40589090) (← links)
• Identification of risk factors in patients treated for first relapse of Hodgkin's disease (Q40599134) (← links)
• Treatment of relapsed Hodgkin's disease (Q40927808) (← links)
• Phase-II trial with M-CAVe-CEC as a salvage chemotherapeutic regimen for early relapsed or primary refractory Hodgkin's disease (Q47338080) (← links)
• Recombinant human granulocyte macrophage colony stimulating factor following alternating non cross resistant chemotherapy in hodgkin's disease (Q54286027) (← links)
• Prognostic Factors (Q62096508) (← links)
• Prognostic factors in Hodgkin's disease (Q62096688) (← links)
• Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease (Q67705350) (← links)
• High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival (Q71571874) (← links)
• Results of CAV regimen (CCNU, Melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease (Q71643803) (← links)
• Late relapses in Hodgkin's disease: Outcome of patients relapsing more than twelve months after primary chemotherapy (Q72105852) (← links)
• Management of relapsed Hodgkin's disease patients with high-dose chemotherapy and marrow stem-cell transplantation (Q74170626) (← links)
• CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma (Q74234766) (← links)
• [Pathogenesis and therapy of Hodgkin lymphoma] (Q74451134) (← links)
• Hodgkin's disease (Q77635506) (← links)